IMUX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Immunic receives notice of allowance for United States patent protecting Vidofludimus Calcium's dose strengths in progressive multiple sclerosisSep 9, 2025
- Immunic reports new positive long-term open-label extension data from Phase 2 EMPhASIS trial of Vidofludimus Calcium in relapsing-remitting multiple sclerosisJun 24, 2025
- Immunic completes enrollment in Phase 3 ENSURE trials for relapsing MS and highlights positive Phase 2 CALLIPER results in progressive MSJun 5, 2025